Landmark Pancreatic Cancer Treatment Paves Way for Targeting Other Tricky Tumors—Scientific American

Read article—Features Michael Cole, a professor of molecular and systems biology, in an article examining new approaches to targeting MYC, a cancer-driving protein long considered "undruggable." The article highlights a breakthrough pancreatic cancer drug targeting RAS proteins and reports that Cole is investigating compounds that could block MYC's ability to activate certain other genes involved in tumor growth.  (Similar coverage in MisrYoum.)